RESEARCH ARTICLE

Ocular immune responses, *Chlamydia trachomatis* infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community

Athuman M. Ramadhani1,2*, Tamsyn Derrick1,2, David Macleod3, Patrick Massae2, Alweda Malisa2, Kelvin Mbuya2, Tara Mtuy1,2, William Makupa2, Chrissy H. Roberts1, Robin L. Bailey1, David C. W. Mabey1, Martin J. Holland1, Matthew J. Burton1

1 Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, 2 Kilimanjaro Christian Medical Centre, Moshi, Tanzania, 3 Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom

* Athuman.Ramadhani@lshtm.ac.uk

Abstract

**Background**

Trachoma, caused by *Chlamydia trachomatis*, remains the leading infectious cause of blindness worldwide. Persistence and progression of the resulting clinical disease appears to be an immunologically mediated process. Azithromycin, which is distributed at the community level for trachoma control, has immunomodulatory properties. We investigated the impact of one round of oral azithromycin on conjunctival immune responses, *C. trachomatis* infection and clinical signs three- and six-months post treatment relative to three pre-treatment time-points.

**Methodology**

A cohort of children aged 6 to 10 years were recruited from a trachoma endemic region of northern Tanzania and were visited five times in a 12-month period. They were examined for clinical signs of trachoma and conjunctival swabs were collected for laboratory analysis. *C. trachomatis* infection was detected and the expression of 46 host genes was quantified using quantitative PCR. All community members were offered azithromycin treatment immediately after the six-month timepoint according to international guidelines.

**Findings**

The prevalence of *C. trachomatis* infection and inflammatory disease signs were significantly reduced three- and six-months post-mass drug administration (MDA). *C. trachomatis* infection was strongly associated with clinical signs at all five time-points. A profound anti-inflammatory effect on conjunctival gene expression was observed 3 months post-MDA,
however, gene expression had largely returned to pre-treatment levels of variation by 6 months. This effect was less marked, but still observed, after adjusting for *C. trachomatis* infection and when the analysis was restricted to individuals who were free from both infection and clinical disease at all five time-points. Interestingly, a modest effect was also observed in individuals who did not receive treatment.

**Conclusion**

Conjunctival inflammation is the major clinical risk factor for progressive scarring trachoma, therefore, the reduction in inflammation associated with azithromycin treatment may be beneficial in limiting the development of potentially blinding disease sequelae. Future work should seek to determine whether this effect is mediated directly through inhibition of pro-inflammatory intracellular signalling molecules, through reductions in concurrent, sub-clinical infections, and/or through reduction of infection exposure.

**Author summary**

Trachoma, caused by conjunctival infection with *Chlamydia trachomatis*, remains the leading infectious cause of blindness. Repeated infection during childhood can trigger prolonged inflammation, which is the main risk factor for conjunctival scarring. Azithromycin is distributed globally for trachoma control, however it is also widely reported to have immunomodulatory properties. This report investigated the impact of one round of oral azithromycin for trachoma control on conjunctival immune responses, clinical signs and *C. trachomatis* infection in Tanzanian children. A large anti-inflammatory effect of azithromycin on conjunctival gene expression was observed 3 months post-treatment, however, gene expression patterns had mostly resumed to pre-treatment levels by 6 months. The effect was evident after adjusting for *C. trachomatis* infection and when analysis was restricted to uninfected individuals, however it was also observed to a lesser extent in individuals that did not receive treatment. These findings suggest that azithromycin may have a direct immunomodulatory effect on conjunctival gene expression but that it may also reduce inflammation by reducing exposure to *C. trachomatis* and other infections. This anti-inflammatory effect could have therapeutic potential in limiting the development of disease sequelae, that goes beyond its effect on the clearance of ocular *C. trachomatis* infection.

**Introduction**

Trachoma remains the leading infectious cause of blindness worldwide, with the greatest burden in sub-Saharan Africa [1]. Trachomatous disease is initiated by repeated conjunctival infection with *Chlamydia trachomatis*, which triggers prolonged inflammatory episodes that contribute to the development of conjunctival scarring [2]. Infection and clinical signs of active trachoma (follicular and papillary inflammation) are most frequently found in younger children [3]. Conjunctival scarring gradually accumulates through childhood, adolescence and into adult life. Eventually this results in the in-turning of the eyelid (entropion) and eyelashes (trichiasis), abrasion of the eyelashes against the cornea, severe visual impairment and blindness in later life. According to recent World Health Organisation
(WHO) estimates, around 165.1 million people live in trachoma-endemic areas (of whom 89% are from WHO’s African region) [4] and 2.8 million have trichiasis [5]. The WHO advocates the use of the SAFE Strategy for trachoma control: Surgery to correct trichiasis, Antibiotics to treat C. trachomatis infection, Facial cleanliness and Environmental improvements to suppress transmission [6].

Annual mass drug administration (MDA) with oral azithromycin for a minimum of 3 years is recommended for communities where the initial prevalence of the clinical sign trachomatous inflammation-follicular (TF) is ≥10% in children aged 1 to 9 years, with a recommended coverage of 80% of the whole community [7]. In low-prevalence settings this usually leads to a sustained reduction in C. trachomatis infection prevalence over time [8–11], however in highly endemic areas infection can re-emerge shortly after MDA [12].

Inflammatory disease signs are reported to persist longer than infection at both the individual and population levels, resulting in the observation of clinical signs in the absence of infection [13–16]. The correlation between clinical signs and C. trachomatis infection in communities prior to MDA is further reduced following treatment [14].

Previously we reported on the relationship between clinical signs, C. trachomatis infection and the expression of 91 immuno-fibrogenic and cell marker genes at the baseline time-point of a long-term cohort study of Tanzanian children [17]. We found an increase in transcripts related to Th1 and NK cell activity in individuals with C. trachomatis infection and an increase in matrix and fibrogenic factors in individuals with active disease in the absence of infection, supporting the findings of several earlier studies [16, 18–24]. However, the changes of these transcriptional responses in an untreated population and the changes that might occur following MDA with azithromycin have not previously been investigated.

Azithromycin is a macrolide antibiotic which has anti-inflammatory and immunomodulatory properties via inhibition of the transcription factor Nuclear Factor Kappa-B [25]. Azithromycin has been reported in vitro to suppress T-cell proliferation and activation and to reduce the expression of mucins and pro-inflammatory cytokines [26–28]. As a result azithromycin is found to be beneficial in the treatment of diseases characterised by pathological inflammation [29]. Azithromycin therefore has the potential to exert broad anti-inflammatory effects on conjunctival gene expression, independently of the clearance of C. trachomatis.

Here we investigate the changes in clinical signs of trachoma, C. trachomatis infection and host immune responses in a cohort of Tanzanian children three- and six-months post azithromycin MDA relative to three pre-treatment time-points. We also investigate the associations between clinical signs, infection and immune responses before and after MDA. This investigation uses data from the first five time-points of a four-year longitudinal study, the baseline findings of which have previously been reported [17].

Methods

Ethics statement

This study was reviewed and approved by the Ethics Committees of the Tanzania National Institute for Medical Research, Kilimanjaro Christian Medical University College and the London School of Hygiene & Tropical Medicine. The study adhered to the tenets of the Declaration of Helsinki. A field worker explained the nature of the study in detail in either Kiswahili or Maasai. Prior to enrolment of a child into this study, their parent or guardian provided written informed consent, on a consent form in Kiswahili, which was witnessed by a third person.
Study design and population

This study was conducted in three adjacent trachoma endemic communities in Kilimanjaro and Arusha regions, Northern Tanzania. In January 2012 we recruited a cohort of children aged 6–10 years from these communities to study the pathogenesis of trachomatous conjunctival scarring. The cohort has subsequently been followed-up every three months for four years. All children aged 6–10 years, who were normally resident in the three villages, were eligible for inclusion. We chose this restricted age group as we considered that they were more likely to show evidence of incident or progressive conjunctival scarring during the four years of the study. The investigation presented in this paper is nested within this overall longitudinal study and uses data from the first five time-points only. The objectives of this nested investigation were to examine changes in C. trachomatis infection, clinical signs of trachoma and host immune responses, and the associations between them, three- and six-months post treatment relative to three pre-treatment time-points.

The study population and participant recruitment process are described in more detail in the report of baseline (time-point 1) findings [17]. In brief, these villages are relatively remote, geographically neighbours and have similar patterns of life and traditions. This area is predominately inhabited by people of the Maasai ethnic group. Pastoral activities are the main occupation. The area is dry for much of the year, except for the rainy season (February to May). Water supply is therefore limited, and largely depends on a long-distance water pipe scheme from Mount Kilimanjaro. Family units are organised in Boma, with living huts arranged in a circle around a central animal enclosure, which is often characterised by a high density of flies.

Clinical assessments and sample collection

We visited the cohort of children every three months at their homes or schools. An experienced ophthalmic nurse examined their left eye for clinical signs of trachoma using x2.5 loupes and a bright torch. Signs were graded using the 1981 WHO ‘FPC’ detailed grading system [30]. This sub-divides the features into several four-point severity scales: follicles (F), papillary inflammation (P) and conjunctival scarring (C). This system corresponds to the WHO Simplified Trachoma Grading System in the following way: Trachomatous inflammation-Follicular (TF) is equivalent to F2/F3 and Trachomatous inflammation-Intense (TI) is equivalent to P3 [31]. Where we refer to “Active Trachoma”, we follow the widely used definition of TF (F2/3) and/or TI (P3). However for the purpose of this study, we also consider that both P2 and P3 represent clinically significant papillary inflammation, and refer to this as “TP” [18]. High resolution photographs (Nikon D90 camera with 105mm Macro lens) were taken of the examined eye for independent grading.

The conjunctiva of the left eye was anaesthetised with a drop of preservative-free proxymetacaine hydrochloride 0.5% w/v (Minims, Chauvin Pharmaceuticals Ltd, Surrey, UK). Two conjunctival swab samples (Dacron polyester, Puritan Medical Products Company, Maine, USA) were collected for C. trachomatis detection and gene expression analysis. The swabs were passed across the upper tarsal conjunctiva four times, with a quarter turn between each pass. The first swab was placed directly into a tube containing RNAlater solution (Thermo Fisher Scientific, Massachusetts, USA) and the second into a dry tube. The samples were placed into a cool box. Later the same day the dry swab samples were stored directly at -80°C and the RNAlater samples kept at 4–8°C overnight and then stored at -80°C.

Trachoma control measures

The SAFE Strategy is being implemented in this region of Tanzania. Community members who had trachomatous trichiasis were offered free surgery in the local health facility.
Azithromycin MDA was distributed to the members of the three villages by our field team under the auspices of the Tanzanian National NTD Control Programme in the Ministry of Health and with supervision by district eye coordinators. Azithromycin, donated to the National NTD Control Programme by Pfizer through the International Trachoma Initiative, was offered to all community members over the age of 6 months. Single-dose azithromycin MDA (1g for adults and 20mg/kg for children) was distributed annually for three years. For infants under six months, tetracycline eye ointment was provided to their primary carer to be applied twice a day to both eyes for six weeks. The project team provided repeated health education messages around hygiene and sanitation. The first round of MDA was administered to all individuals in the three cohort villages immediately after time-point 3. No adverse effects were reported.

**C. trachomatis detection**

Two protocols were used for both genomic DNA extraction and *C. trachomatis* detection. For time-point 1 samples, genomic DNA was extracted from dry swabs using the PowerSoil DNA isolation Kit (MO Bio Laboratories, California, USA) according to manufacturer’s instructions. For time-points 2 to 5, genomic DNA was extracted from samples stored in RNAlater using the Norgen DNA/RNA Purification Kit (Norgen Biotek Corp, Canada) following the manufacturer’s instructions.

*C. trachomatis* was detected in the time-point 1 samples using a droplet digital PCR assay (ddPCR) and at time-points 2 to 5 using multiplex quantitative real-time PCR (qPCR) previously evaluated against ddPCR [17, 32, 33]. Both assays detect chlamydial plasmid open reading frame 2 (pORF2), *C. trachomatis* outer membrane complex protein B (omcB) and human endogenous control gene ribonuclease P/MRP Subunit P30 (RPP30) [33], using the same primer and probe sequences. The ddPCR reaction contained 5μl of DNA template and primers/probes at a final concentration of 0.3nM using Taqman mastermix. PCR reaction conditions were as follows: 95˚C for 10 minutes, then 40 cycles of 95˚C for 10 seconds and 60˚C for 30 seconds and finally 98˚C for 12 minutes. Droplets were then examined for fluorescence on a QX200TM Droplet Reader (Bio-Rad, UK), providing a quantitative result. The qPCR assay was performed on a ViiA7 thermal cycler (Thermo Fisher Scientific, Massachusetts, USA) using TaqMan Multiplex Master mix in a final volume of 20 μl, containing 4μl of DNA template and primers and probes each at a final concentration of 0.3nM. Cycling conditions were as follows: 95˚C hold for 20 seconds followed by 40 cycles of 95˚C for 1 second and 60˚C for 20 seconds. Samples were tested in duplicate and were considered *C. trachomatis* positive if either replicate amplified omcB and/or pORF2 with a cycle threshold (CT) value <40. In order to compare agreement between ddPCR and qPCR assays, Norgen-extracted DNA from time-point 2 samples (extracted from the first swab stored in RNAlater) were tested using both methods and the results are shown in S1A Table.

**Analysis of human gene expression**

Total RNA was extracted from samples stored in RNAlater using the Norgen DNA/RNA Purification Kit (Norgen Biotek Corp, Canada) and reverse transcribed using the SuperScript VILO cDNA Synthesis Kit (Life Technologies) following the manufacturer’s instructions. Relative abundance of host gene targets was quantified by real-time PCR using customized TaqMan Microfluidic 384-well Array Cards (Thermo Fisher Scientific, Massachusetts, USA) on a ViiA7 real-time PCR machine (Thermo Fisher Scientific, Massachusetts, USA), as previously described [17]. A total of 46 genes of interest were selected based on our previously reported time-point 1 findings, in which we selected genes that were significantly associated with...
clinical signs and/or *C. trachomatis* infection status. *HPRT1* was included to each PCR run as an endogenous control gene.

**Statistical analysis**

Data were managed in Microsoft Access. The ΔCT method was used to adjust for the concentration of input RNA by subtracting the cycle threshold (CT) value of each gene from the CT value of *HPRT1* in the same sample [34]. The distribution of ΔCT values were plotted to assess normality. Host gene expression, *C. trachomatis* infection and clinical data were analysed in STATA v14.

For each time-point the prevalence of clinical signs and *C. trachomatis* infection was estimated and the association between infection and each of TF and TP was estimated using logistic regression. The effect of MDA on infection, TF, TP and AT (Active Trachoma) was estimated using a random effects logistic regression. Each of infection, TF, TP and AT were used as the outcome variable in four separate regressions, the observations from the first three time-points were compared with the observations from time-point 4 (the first observation after the MDA) and participant ID was included as a random effect to account for the fact that these were repeated observations within individuals. An identical analysis was repeated comparing the observations from time-point 5 to those from before MDA to assess whether the estimated effect persisted at six months post treatment.

The change in mean ΔCT value from time-point 1 was plotted for 46 genes at each of the four subsequent time-points and inspected to identify any clear differences between time-points. The change in mean ΔCT following MDA was formally tested by comparing the mean ΔCT in the first three time-points with that from the fourth time-point using a random effects linear regression, with the ΔCT value of each gene as the outcome variable, whether an observation was before or after MDA as the exposure. Participant ID was included as a random effect to again account for repeated observations of the same individuals. An interaction term was included between before/after MDA and whether an individual was actually treated or not to assess the evidence of whether gene expression response after MDA was different in the treated and the untreated groups. These analyses were also repeated comparing the fifth time-point with the three pre-MDA time-points to identify if the effect persisted. Gene expression was then compared at time-point 4 only between treated and untreated individuals. These analyses were initially performed unadjusted and then adjusted for infection status (clinical signs were not adjusted for as they were likely to be caused by both infection and gene expression, rather than the other way around so adjusting for these could bias our estimates). The Benjamini and Hochberg method was used to control for the false discovery rate of 5% [35].

Multivariable linear regression was used at each of the five time-points presented in this report, to test the association of each gene’s expression with clinical signs and infection, adjusting for age and sex and assuming a false discovery rate (FDR) of 5% in multiple comparisons [35].

A Preferred Reporting Item (STROBE_checklist_cohort 2-12-18) is included in the supporting information. Accession numbers for each gene included in this analysis are included at the end of this manuscript. The protocols used in our analyses are accessible on protocols.io website using the accession number https://dx.doi.org/10.17504/protocols.io.zyhf7t6

**List of accession numbers for genes**

HPRT1-Hs02800695, ALOX5-Hs01095330, CCL18-Hs00268113, CCL2-Hs00234140, CCL20-Hs01011368, CD247-Hs00234140, CDH1-Hs01023894, CDH2-Hs00983056, CXCL13-Hs00757930, CXCL5-Hs01099660, DEFB4B;
Results

Study participants

At census we registered a total of 666 children aged between 6 and 10 years who were eligible for recruitment at the beginning of this study from three trachoma-endemic villages. At time-point one 506 participants were assessed; their demography, clinical signs and infection status have previously reported in detail [17]. In general participants were predominantly from the Maasai ethnic group (652/666, 97.9%) with a similar number of males (332, [49.9%]) and females (334 [50.1%]) and a mean age of 7.01 years (SD 2.0) at the time of commencing the study. At each time-point some children were not examined due to being absent in the village, having moved away or declining to participate. After time-point 1, the recruitment of new participants into the longitudinal study was permitted at the second time-point only. MDA was offered immediately after time-point 3 to all members of the three cohort villages. The reported community-wide coverage was 68.7%. All study participants examined in time-point 3 (466) were treated except one who refused. At time-point 4, 392/466 (84.1%) of the individuals seen had been treated.

Clinical signs of trachoma

At time-point 1 the clinical signs previously reported were based on grading of conjunctival photographs, to enable subsequent comparison with the final time-point for determination of scarring incidence and progression [17]. However, for consistency within this analysis of the first five time-points, the field grading data was used. The agreement between field and photograph grading for time-point 1 is shown in S1B Table. Kappa scores between field and photographs grading were 0.92 for TF and 0.68 for TP, with TP being slightly under-reported by field graders.

The prevalence of TF in the first three time-points prior to MDA was fairly consistent (171/506 [33.8%], 163/537 [30.2%] and 104/467 [22.3%]), dropping to 52/467 (11.1%) and 61/479 (12.6%) post-MDA at time-points 4 and 5 (Fig 1). The prevalence of TP was consistently lower than TF and also dropped substantially following MDA (Fig 1). There were no statistically significant differences between males and females in terms of the proportion showing signs of TF and/or TP at any time-point (S2 Table), with the exception of time-point 1 where there was possibly a weak association between TP and female sex.

C. trachomatis infection

The prevalence of infection was fairly consistent prior to MDA, dropping very slightly from 15.4% and 15.3% at time-points 1 and 2 to 11.6% at time-point 3. Three months after azithromycin MDA (time-point 4) infection prevalence dropped to 1.3% and then increased slightly
to 2.5% at time-point 5 (Fig 1). There was strong evidence for an association between *C. trachomatis* infection and clinical signs (TF, TP) at all five time-points (Table 1), with the exception of TP at time-point 5. There was a significant reduction in TF, TP and *C. trachomatis* detection in post-MDA time-points 4 and 5 relative to the combined odds at pre-MDA time-points 1–3 (Table 2). The inflammatory disease (TF and/or TI (active trachoma)) and infection status for each individual at each time-point is shown in Fig 2; participants were grouped by infection and disease status at baseline. There were no statistically significant differences between males and females in terms of the proportion testing positive for *C. trachomatis* at any time-point (S2 Table).

![Fig 1. The prevalence of *C. trachomatis* infection and clinical signs before and after MDA. At time-points 1, 2, 3, 4, and 5 data are shown for 506, 537, 466, 467 and 477 children respectively.](https://doi.org/10.1371/journal.pntd.0007559.g001)

### Table 1. The association between *C. trachomatis* detection and clinical signs by time-point.

Clinical signs are based on field grading from all five time-points.

| Time-point | Follicular Inflammation (TF) | Papillary inflammation (TP) |
|------------|-------------------------------|-----------------------------|
|            | No TF (%)                     | TF (%)                      | No TP (%) | TP (%)          |
| 1 (n = 506) | Ct infected (%)               | 18/335 (5.4)               | 60/171 (35.1) | 38/407 (9.3) | 40/99 (40.4) |
|            | OR (95%CI)                    | -                           | 9.52 (5.4–16.8) | - | 6.58 (3.9–11.1) |
|            | p-value                       | -                           | <0.0001     | - | <0.0001     |
| 2 (n = 536) | Ct infected (%)               | 29/374 (7.8)               | 53/162 (32.7) | 38/429 (8.9) | 44/107 (41.1) |
|            | OR (95%CI)                    | -                           | 5.78 (3.5–9.5) | - | 7.19 (4.3–12.0) |
|            | p-value                       | -                           | <0.0001     | - | <0.0001     |
| 3 (n = 466) | Ct infected (%)               | 19/362 (5.3)               | 35/104 (33.7) | 30/398 (7.5) | 24/68 (35.3) |
|            | OR (95%CI)                    | -                           | 9.16 (4.9–16.9) | - | 6.69 (3.6–12.5) |
|            | p-value                       | -                           | <0.0001     | - | <0.0001     |
| **Azithromycin MDA** |                  |                             |             |             |             |
| 4 (n = 467) | Ct infected (%)               | 3/415 (0.7)                | 3/52 (5.8)    | 4/457 (0.9) | 2/10 (20.0)  |
|            | OR (95%CI)                    | -                           | 8.41 (1.7–42.8) | - | 28.31 (4.5–177.5) |
|            | p-value                       | -                           | 0.010       | - | <0.0001     |
| 5 (n = 477) | Ct infected (%)               | 4/417 (1.0)                | 8/60 (13.1)   | 10/442 (2.3) | 2/35 (5.7)   |
|            | OR (95%CI)                    | -                           | 15.88 (4.6–54.5) | - | 2.62 (0.6–12.4) |
|            | p-value                       | -                           | <0.0001     | - | 0.226       |

https://doi.org/10.1371/journal.pntd.0007559.t001
Conjunctival gene expression

Forty-six genes of interest were quantified in all individuals who were sampled at each of the five time-points. All amplified targets were included in the analyses. For each time-point, multivariate linear regression models were constructed for expression of each gene to investigate associations with TF, TP and C. trachomatis infection, adjusting for age and sex (S3 Table).

The associations between the expression of specific genes with clinical signs and C. trachomatis infection was similar at each time-point and was consistent with the baseline (time-point 1) report [17]. Briefly, in individuals with C. trachomatis infection, IFNG, IL22, CCL2, IL12B, CD274, IL21, IL17A and SOCS1 genes were consistently the most upregulated and S100A4, ALOX5, MMP7, MUC5AC, MUC7, MUC4, MUC1, CDH2 and CDH1 genes were the most downregulated. In individuals with TF and TP, S100A7, CCL18, MMP12, CXCL13, IL10, IL19, IL21 and IL17A were the most upregulated while S100A4, SPARCL1, ALOX5 and MUC5AC were the most downregulated.

For each target, the difference in mean gene expression (across all individuals) was calculated at each time-point relative to the mean expression at time-point 1 (Fig 3). There was only modest variability between these time-points, with the exception of time-point 4, three months after MDA, which showed marked differences compared to time-point 1 (and the other time-points). The largest increases in expression at time-point 4 relative to time-point 1 were found in

Table 2. Comparison of C. trachomatis infection and disease signs between the pre-treatment (odds of time-points 1, 2 and 3) to the post-treatment time-points (4 and 5 analysed separately). Clinical signs are based on field grading from all five time-points.

|                          | Infection | TF    | TP    | Active Trachoma |
|--------------------------|-----------|-------|-------|-----------------|
| **Combined odds of pre-MDA time-points vs. time-point 4 (3 months post-MDA)** | OR        | 0.01  | 0.10  | 0.03            | 0.08 |
|                          | (95%CI)   | (0.004–0.04) | (0.06–0.17) | (0.01–0.07)  | (0.05–0.13) |
|                          | p-value   | <0.0001 | <0.0001 | <0.0001       | <0.0001 |
| **Combined odds of pre-MDA time-points vs. time-point 5 (6 months post-MDA)** | OR        | 0.04  | 0.15  | 0.18            | 0.14 |
|                          | (95%CI)   | (0.02–0.10) | (0.10–0.23) | (0.11–0.30)  | (0.10–0.22) |
|                          | p-value   | <0.0001 | <0.0001 | <0.0001       | <0.0001 |

https://doi.org/10.1371/journal.pntd.0007559.t002

Fig 2. The clinical disease (Active Trachoma) and infection status of individuals at each time-point, ordered by status at baseline. Each row represents an individual and each column represents a time-point.

https://doi.org/10.1371/journal.pntd.0007559.g002
SPARC1, MUC5AC, CDH2, CTGF, NCAM1, CDH1, MUC7, S100A4, and IL12B (Fig 3). The largest decreases were in S1007A, CCL18, CXCL5, DEFB4A, CXCL13, IL19, MMP12, IDO1, IL1B, and IL17A (Fig 3). By time-point 5, six months after MDA, difference in mean gene expression had mostly returned to levels that were similar to those prior to treatment (Fig 3).

The change in mean ΔCT for the expression of each gene from the three time-points before MDA to the fourth time-point three months after MDA was estimated for all participants, and also separately for both individuals who received MDA and those who did not, adjusting for changes in C. trachomatis infection status (Table 3). This showed a significant change in mean ΔCT of most targets from before MDA compared with three months after MDA. Interestingly, this change was still observed in the untreated sub-group, albeit at a much reduced scale. The changes in mean ΔCT were larger when the analysis was not adjusted for C. trachomatis infection (S4 Table).

To investigate the differences between the treated and untreated groups further, mean ΔCT were compared between the groups at time-point 4 only (S5 Table). This revealed only subtle differences in mean ΔCT between treated and untreated individuals. The anti-inflammatory effect of MDA on gene expression was observed even in individuals without any detectable episodes of chlamydial infection or clinical disease (F0, P0) at any of these five time-points (S6 Table).

**Discussion**

**Infection**

The prevalence of C. trachomatis was similar across the three time-points before MDA, suggesting that the infection prevalence was relatively stable in this antibiotic-naïve community at around 11% - 16%. The drop in the prevalence of infection and clinical signs at time-point 3 may have been due to medium term natural variation in the prevalence, as strains of Chlamydia trachomatis come and go, due to the introduction of public health education to the communities by the field team or possibly due to the change in seasons. There was a...

---

**Fig 3. Variation in conjunctival gene expression.** The difference in mean ΔCT value (across all individuals) for each gene at time-points 2, 3, 4 and 5 is shown relative to time-point 1. Values are adjusted for C. trachomatis infection and active trachoma and are ordered by difference in mean gene expression at Time-point 4.

https://doi.org/10.1371/journal.pntd.0007559.g003
Table 3. Estimated Fold Changes (FC) with their respective p-values comparing the expression of each gene pre-MDA (time-points 1, 2 and 3) and post-MDA (time-point 4). A FC of >1 indicates increased expression of the gene after MDA. Column 1 includes all participants, columns 2 and 3 show the results stratified by whether an individual actually received the treatment or not. The final column (p-value for interaction) assesses the evidence as to whether the fold change from before to after MDA is different in the treated and untreated groups. Results are ordered by FC of “All” individuals (column 1).

| Target | All FC | p-value | Untreated Only FC | p-value | Treated Only FC | p-value | p-value for interaction |
|--------|--------|---------|------------------|---------|----------------|---------|------------------------|
| SPARCL1 | 11.89 7.76 x10^-186 | 6.81 9.04 x10^-19 | 13.13 2.54 x10^-173 | 0.005 | | |
| MUC5AC | 4.02 3.95 x10^-145 | 2.89 1.20 x10^-14 | 4.26 5.35 x10^-136 | 0.009 | | |
| CDH2 | 3.42 2.97 x10^-141 | 2.67 9.16 x10^-16 | 3.58 3.30 x10^-130 | 0.026 | | |
| NCAM1 | 2.23 9.10 x10^-89 | 1.83 1.95 x10^-9 | 2.31 8.32 x10^-83 | 0.031 | | |
| CTGF | 2.20 3.57 x10^-96 | 2.25 1.27 x10^-17 | 2.20 4.10 x10^-81 | 0.818 | | |
| MUC7 | 1.89 7.10 x10^-29 | 2.17 1.01 x10^-7 | 1.84 2.24 x10^-23 | 0.291 | | |
| SI00A4 | 1.82 7.83 x10^-79 | 1.75 1.56 x10^-12 | 1.83 5.50 x10^-69 | 0.612 | | |
| CDH1 | 1.72 1.23 x10^-80 | 1.69 9.80 x10^-14 | 1.72 2.55 x10^-69 | 0.808 | | |
| FG2 | 1.50 2.86 x10^-9 | 1.48 0.019 | 1.50 4.19 x10^-8 | 0.934 | | |
| SERPINB4 | 1.43 1.91 x10^-3 | 1.65 0.067 | 1.39 0.009 | 0.570 | | |
| IL12B | 1.42 5.47 x10^-15 | 1.49 4.10 x10^-4 | 1.41 1.97 x10^-12 | 0.657 | | |
| TGFBI | 1.34 2.53 x10^-45 | 1.43 4.80 x10^-12 | 1.33 6.55 x10^-36 | 0.178 | | |
| ALOX5 | 1.29 7.49 x10^-39 | 1.37 7.71 x10^-11 | 1.27 1.24 x10^-30 | 0.133 | | |
| MUC1 | 1.24 8.04 x10^-17 | 1.35 4.05 x10^-6 | 1.22 9.95 x10^-13 | 0.161 | | |
| NCR1 | 1.23 2.51 x10^-10 | 1.25 0.007 | 1.23 7.76 x10^-9 | 0.835 | | |
| PDGFBI | 1.22 7.96 x10^-14 | 1.35 1.26 x10^-5 | 1.20 2.59 x10^-10 | 0.130 | | |
| GAPDH | 1.20 5.05 x10^-11 | 1.49 1.68 x10^-8 | 1.16 1.33 x10^-6 | 0.001 | | |
| SOCS1 | 1.20 2.64 x10^-8 | 1.49 5.69 x10^-7 | 1.15 6.66 x10^-5 | 0.003 | | |
| MUC4 | 1.16 1.80 x10^-7 | 1.34 6.1 x10^-5 | 1.13 6.01 x10^-5 | 0.034 | | |
| VIM | 1.15 9.83 x10^-10 | 1.22 4.08 x10^-4 | 1.14 2.11 x10^-7 | 0.242 | | |
| CD247 | 1.01 0.757 | 1.10 0.196 | 0.99 0.856 | 0.205 | | |
| MMP9 | 0.95 0.242 | 0.98 0.083 | 0.95 0.024 | 0.731 | | |
| IFNG | 0.95 0.219 | 0.93 0.521 | 0.95 0.293 | 0.860 | | |
| MMP7 | 0.93 0.033 | 1.08 0.441 | 0.90 0.009 | 0.086 | | |
| IL23A | 0.88 5.88 x10^-4 | 1.00 0.989 | 0.86 1.73 x10^-4 | 0.127 | | |
| IL22 | 0.83 0.020 | 1.26 0.232 | 0.76 0.002 | 0.016 | | |
| IL6 | 0.83 5.24 x10^-4 | 0.83 0.150 | 0.83 0.001 | 0.959 | | |
| CCL20 | 0.82 3.80 x10^-6 | 0.92 0.447 | 0.80 2.29 x10^-6 | 0.240 | | |
| IL8 | 0.72 1.42 x10^-18 | 0.72 4.81 x10^-4 | 0.72 4.02 x10^-16 | 0.980 | | |
| PTGSI | 0.70 1.97 x10^-17 | 0.79 0.0252 | 0.69 8.27 x10^-17 | 0.210 | | |
| DUOX2 | 0.69 7.01 x10^-25 | 0.87 0.134 | 0.67 1.81 x10^-26 | 0.006 | | |
| IL10 | 0.67 7.68 x10^-24 | 0.80 0.026 | 0.64 6.84 x10^-24 | 0.047 | | |
| M2B1 | 0.65 3.20 x10^-17 | 0.71 0.008 | 0.64 6.23 x10^-16 | 0.466 | | |
| CD274 | 0.63 6.37 x10^-37 | 0.77 0.004 | 0.61 1.28 x10^-36 | 0.018 | | |
| CCL2 | 0.60 2.63 x10^-22 | 0.63 5.52 x10^-4 | 0.59 5.94 x10^-20 | 0.617 | | |
| SOCS3 | 0.59 1.13 x10^-38 | 0.76 0.006 | 0.57 5.67 x10^-39 | 0.007 | | |
| IL1B | 0.52 1.78 x10^-43 | 0.61 2.81 x10^-5 | 0.50 1.55 x10^-40 | 0.140 | | |
| IL21 | 0.51 3.18 x10^-24 | 0.72 0.044 | 0.48 1.03 x10^-24 | 0.022 | | |
| IL17A | 0.48 6.01 x10^-44 | 0.64 7.36 x10^-4 | 0.46 2.57 x10^-43 | 0.017 | | |
| IDO1 | 0.44 6.25 x10^-90 | 0.68 1.69 x10^-4 | 0.41 4.74 x10^-93 | 9.55 x10^-6 | | |
| MMP12 | 0.43 9.98 x10^-70 | 0.56 1.87 x10^-6 | 0.41 6.82 x10^-67 | 0.018 | | |
| IL19 | 0.40 5.00 x10^-63 | 0.55 1.42 x10^-5 | 0.37 4.32 x10^-61 | 0.012 | | |
| CXCL5 | 0.39 2.79 x10^-65 | 0.61 3.88 x10^-4 | 0.36 6.18 x10^-66 | 7.64 x10^-4 | | |
| DEF44A | 0.38 1.32 x10^-64 | 0.52 1.16 x10^-5 | 0.36 1.94 x10^-62 | 0.015 | | |
substantial reduction in infection prevalence at three months post-MDA, however, it rose slightly by six months post-MDA, suggesting some limited re-emergence of infection. This may be due to insufficient MDA coverage within the community, contact with individuals from surrounding untreated communities, or failure to complete the 6-week daily treatment course of tetracycline eye ointment for infants under 6 months. Members of these communities travel quite frequently to search for pastures and water for livestock, to visit markets and for social interactions with other communities. As a result, it was difficult to achieve high MDA coverage. Previous studies from Tanzania and The Gambia have also reported on the importance of contact between communities as a risk factor for reinfection following treatment [10, 11, 36].

Disease
Clinical signs of inflammation were strongly correlated with *C. trachomatis* infection at all five time-points. In our previous systematic review and meta-analysis we found a strong correlation between TF and *C. trachomatis* infection and a moderate correlation between intense papillary inflammation (TI) and infection prior to initiation of MDA, however after treatment the correlation was weaker for TF and no correlation was found for TI [14]. Most of these earlier studies included multiple rounds of MDA and reported data several years after initiating treatment, therefore it might be too early to see this trend in our cohort. There was no consistent difference in the prevalence of clinical signs of inflammation between males and females, with the exception of the first timepoint which showed a non-significant trend of more TP in females.

Gene expression
Our findings in this study of the associations between host gene expression, *C. trachomatis* infection and clinical signs of inflammation were consistent with previous reports from ourselves and others [16, 18, 21, 22, 24, 37, 38]. Targets that were consistently associated with clinical signs (TF/TP) at all five time-points included antimicrobial peptides (S100A7), pro-inflammatory cytokines and chemokines (CCL18, CXCL13, IL10, IL19, IL21, IL17A), matrix modifiers (MMP12 and SPARCL1), epithelial-mesenchymal transition markers (S100A4), microbiota responses (ALOX5) and mucins (MUC5AC). Likewise, *C. trachomatis* infection was consistently associated with pro-inflammatory cytokines and chemokines (IFNG, IL22, CCL2, IL12B, IL21, IL17A), regulators/signalling pathways (SOCS1, CD274), S100A4, ALOX5, matrix modifiers (MMP7, SPARCL1) and mucins (MUC7). We discussed the functions of these genes and their potential roles in the clearance of *C. trachomatis* infection and immunopathology in detail in our baseline paper [17]. The results at each of the subsequent time-points support the data from baseline, suggesting that strong IFNG/IL12 responses are important in the clearance of infection, whilst Th17 cell associated cytokines and matrix factors are associated with both infection and the clinical inflammation which persists after infection has been cleared.

Large changes in gene expression were detected at time-point 4, three months after MDA with azithromycin, relative to the three time-points prior to MDA. This variation in gene expression was observed in the following genes:

| Target | All FC p-value | Untreated Only FC p-value | Treated Only FC p-value | p-value for interaction |
|--------|---------------|--------------------------|------------------------|------------------------|
| CXCL13 | 0.38 1.19 x10^-47 | 0.50 3.58 x10^-5 | 0.36 3.28 x10^-45 | 0.067 |
| CCL18  | 0.33 8.10 x10^-49 | 0.47 5.75 x10^-5 | 0.31 7.95 x10^-47 | 0.032 |
| S100A7 | 0.28 4.90 x10^-55 | 0.53 0.002 | 0.25 3.61 x10^-56 | 7.03 x10^-4 |

https://doi.org/10.1371/journal.pntd.0007559.t003
expression largely returned to pre-MDA levels by time-point 5, six months post-MDA. Azithromycin appeared to have an anti-inflammatory effect on gene expression, reversing the direction of gene expression change usually associated with clinical signs and *C. trachomatis* infection. Genes normally downregulated in individuals with *C. trachomatis* infection and/or inflammation were upregulated post-MDA (SPARCL1, MUC5AC, CDH2, CTGF, NCAM1, CDH1, S100A4, MUC7, and FGF2), whilst genes normally upregulated (S100A7, CCL18, CXCL5, CXCL13, IL19, IDO1, MMP12, IL17A, IL1B and IL21) were strongly downregulated post-MDA. The effect was greatest when *C. trachomatis* infection was not adjusted for, however the effect was still large after adjustment for infection, suggesting that azithromycin has an immunomodulatory effect on gene expression that is independent of the concurrent reduction in infection. This effect was also seen in individuals without any episodes of *C. trachomatis* infection and clinical signs of inflammation across all 5 time-points, supporting this hypothesis. However, we cannot exclude the possibility that azithromycin treatment reduced ocular infections with other sub-clinical or mild inflammation-causing organisms in these individuals. Interestingly, a change in mean gene expression post-MDA was also observed in individuals who did not receive treatment. This could be due to a reduction in transmission and therefore exposure to *C. trachomatis* and/or other infectious organisms within the community as a whole.

Azithromycin has previously been reported to have anti-inflammatory effects in humans, animal and *in vitro* models, leading to improved clinical outcomes through a combined approach of clearing infection and reducing pathological host inflammatory responses [39]. One pre-surgical dose of azithromycin reduced the level of pro-inflammatory cytokines and chemokines detected in oral fluid 6 days following dental implant surgery relative to amoxicillin [40]. Relative to other non-macrolide antibiotics, azithromycin reduced levels of IL-6, IL-8, TNF-α and GM-CSF proteins in individuals with pneumonia and rhinovirus infections [41–43]. MMP9 expression was reduced in the airways of lung transplanted individuals treated with azithromycin between 3 and 6 months [44], and in an experimental laminectomy model in rats, azithromycin was associated with reduction of fibrosis and inflammatory cell density six weeks after administration [45]. Immunomodulatory effects of azithromycin are thought to be enhanced by its long half-life in tissue, lasting for several weeks [46, 47]. In addition to localised anti-inflammatory effects, one round of azithromycin, administered for trachoma control, was associated with a large reduction in infectious and all-cause childhood mortality [48]; a finding which was reinforced by a large multi-country placebo-controlled clinical trial [49]. Our findings of an immunomodulatory effect of azithromycin are therefore consistent with published evidence and suggest that MDA for trachoma control may have an additional protective effect through a systemic reduction in inflammation.

This study has several limitations. It was only feasible to sample one eye from study participants, thus only the left eye was examined and sampled throughout the longitudinal study. The age range of study participants was limited due to the study design of the overall longitudinal study, which this investigation was nested within. The method of *C. trachomatis* detection was changed after the first time-point, which could introduce inconsistencies between the infection results of the first relative to later time-points. Agreement between the two methods used was however deemed acceptable (S1A table). The infection loads of discrepant results were very low and at around the limit of detection. Given the large sample size and the use of three pre-MDA time-points, this variation is not expected to significantly alter the results or their interpretation.

**Conclusions**

We present evidence that one round of oral azithromycin treatment exerted a strong anti-inflammatory effect on conjunctival gene expression, detectable three months following
treatment but mostly returning to pre-MDA levels by six months. This effect was also observed in individuals without *C. trachomatis* infection and clinical signs of inflammation across all five time-points, indicating that the immunomodulatory effect was at least in part independent of the reduction of *C. trachomatis* infection. Interestingly, a reduced effect was also seen in individuals who did not receive treatment, which could reflect a community reduction in infection transmission and exposure. A limitation of this study is that we cannot determine whether this effect is mediated directly through inhibition of pro-inflammatory intracellular signalling molecules, through reductions in concurrent, sub-clinical infections, and/or through reduction of infection exposure, and future work should seek to understand these mechanisms. Conjunctival papillary inflammation is a significant risk factor for scarring progression [2], therefore the anti-inflammatory effect of azithromycin might have therapeutic potential in limiting the development of disease sequelae, that goes beyond its effect on the prevalence of ocular *C. trachomatis* infection.

**Supporting information**

S1 Checklist. STROBE checklist.

(DOC)

S1 Table. Table A) 2 x 2 table showing agreement between qPCR and ddPCR assays for *C. trachomatis* detection in DNA extracted from conjunctival swabs at time-point 2. Sensitivity = 82.6% (95% CI 72.8–89.9), Specificity = 96.7% (95% CI 96.7–99.4), NPV = 96.6% (95% CI 94.8–97.6%); PPV = 91.0% (95% CI 82.9–95.5%); Cohens Kappa = 0.84, Accuracy: overall probability that a sample will be correctly classified 95.8% (95% CI 93.7–97.4), for these samples at this prevalence (16.4%) with ddPCR as the reference standard. Table B) Agreement between field and photo grading at baseline (time-point 1) for follicular and papillary inflammation in the conjunctiva. Kappa scores between field and photographs grading were 0.92 for TF and 0.68 for TP.

(DOCX)

S2 Table. The relationship between sex and (i) clinical signs (from field grading) and (ii) *C. trachomatis* infection of each of the 5 time-points. The number of individuals with each clinical phenotype or infection is shown as a proportion of the total number of males and females at each time-point. Associations between sex and clinical phenotypes or infection were tested using logistic regression.

(DOCX)

S3 Table. Multivariable linear regression models for conjunctival gene expression associated with clinical signs, *C. trachomatis*, female sex and age. FC = fold change. Using the Benjamini and Hochberg approach to adjust for multiple comparisons, in order to control the false discovery rate <5% only tests with a p-value below 0.027 are considered statistically significant.

(XLSX)

S4 Table. Estimated Fold Changes (FC) with their respective p-values comparing the expression of each gene between the combined first three time-points (time-points 1, 2 and 3) before MDA and time-point 4 (three months after MDA), not adjusted for *C. trachomatis* infection. A FC of >1 indicates increased expression of the gene at time-point 4. Random effects multivariable linear regression of all individuals (first panel), untreated only (second panel) and treated only (third panel). The final column (p-value for interaction) provides evidence as to whether the fold change from before to after MDA is different in the
treated and untreated groups. Results are ordered by FC of “All” individuals. Benjamini and Hochberg approach was used to adjust for multiple comparisons, in order to control the false discovery rate <5%, only tests with a p-value <0.035 are considered statistically significant.

(S5 Table) Estimated Fold Change (FC) with their respective p-values for the expression of each gene at time-point 4 only (three months post MDA), comparing MDA treated (after time-point 3) to untreated individuals. Multivariable linear regression of all individuals adjusted (first panel) and not adjusted (second panel) for C. trachomatis infection. Results are ordered by FC of adjusted data with infection. Benjamini and Hochberg approach was used to adjust for multiple comparisons, in order to control false discovery rate <5%, only tests with a p-value <0.009 are considered statistically significant.

(S6 Table) Estimated fold changes (FC) with their respective p-values comparing the expression of each gene between the combined first three time-points (1, 2 and 3) before MDA and separately time-points 4 and 5 (three and six months following MDA treatment), in 122 individuals who were free from infection and disease (F0, P0) at all 5 time-points. Results are ordered by Fold Change (FC) in pre-MDA time-points vs. time-point 4. Benjamini and Hochberg approach was used to adjust for multiple comparisons, in order to control the false discovery rate <5%, only tests with a p-value <0.035 are considered statistically significant.

Author Contributions

Conceptualization: Robin L. Bailey, David C. W. Mabey, Martin J. Holland, Matthew J. Burton.

Data curation: Athumani M. Ramadhani, Tamsyn Derrick, David Macleod.

Formal analysis: Athumani M. Ramadhani, Tamsyn Derrick, David Macleod.

Funding acquisition: Martin J. Holland, Matthew J. Burton.

Investigation: Athumani M. Ramadhani, Tamsyn Derrick, Martin J. Holland, Matthew J. Burton.

Methodology: Athumani M. Ramadhani, Tamsyn Derrick, David MacLeod, Patrick Massae, Aiweda Malisa, Kelvin Mbuya, Chrissy H. Roberts, Martin J. Holland, Matthew J. Burton.

Project administration: Athumani M. Ramadhani, Patrick Massae, Aiweda Malisa, Kelvin Mbuya, Tara Mtuy, William Makupa, Martin J. Holland, Matthew J. Burton.

Resources: Patrick Massae, Aiweda Malisa, Tara Mtuy, William Makupa, Martin J. Holland, Matthew J. Burton.

 Supervision: Martin J. Holland, Matthew J. Burton.

Visualization: David Macleod.

Writing – original draft: Athumani M. Ramadhani.

Writing – review & editing: Athumani M. Ramadhani, Tamsyn Derrick, David MacLeod, Tara Mtuy, William Makupa, Chrissy H. Roberts, Robin L. Bailey, David C. W. Mabey, Martin J. Holland, Matthew J. Burton.
References

1. Eliminating Trachoma: Accelerating Towards 2020. WHO, 2016, WHO Alliance for the Global Elimination of Trachoma by 2020: Geneva.

2. Ramadhani A.M., et al., Blinding Trachoma: Systematic Review of Rates and Risk Factors for Progressive Disease. PLoS Negl Trop Dis, 2016. 10(6): p. e0004859. https://doi.org/10.1371/journal.pntd.0004859 PMID: 27483002

3. WHO Alliance for the Global Elimination of Trachoma by 2020: progress report on elimination of trachoma, 2014–2016. Wkly Epidemiol Rec, WHO, 2017. 92(26): p. 359–68.

4. WHO, Weekly Epidemiological Record. WHO, 2018. 93(26): p. 12.

5. Flueckiger, R.M., et al., The global burden of trichiasis in 2016. bioRxiv, 2018.

6. WHO, Global elimination of blinding trachoma. Resolution WHA 51.11. Adopted by the World Health Assembly 16 May 1998. 1998.

7. WHO Alliance for the Global Elimination of Blinding Trachoma: progress report on elimination of trachoma, 2014–2016. Wkly Epidemiol Rec, WHO, 2017. 92(26): p. 359–68.

8. Pant B.P., et al., Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma Program. PLoS Negl Trop Dis, 2016. 10(2): p. e0004462. https://doi.org/10.1371/journal.pntd.0004462 PMID: 26871898

9. Solomon A.W., et al., The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Negl Trop Dis., 2008. 2(12): p. e341. https://doi.org/10.1371/journal.pntd.0000341 PMID: 19048024

10. Burton M.J., et al., Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet., 2005. 365(9467): p. 1321–1328. https://doi.org/10.1016/S0140-6736(05)61029-X PMID: 15823382

11. Bailey R., et al., The duration of human ocular Chlamydia trachomatis infection is age dependent. EpidemioInfect., 1999. 123(3): p. 479–486. https://doi.org/10.1017/s0950268899003076 PMID: 10694161

12. Melese M., et al., Temporal cytokine gene expression patterns in subjects with trachoma identify distinct conjunctival responses associated with infection. Clin.Exp.Immunol., 2005. 142(2): p. 347–353. https://doi.org/10.1111/j.1365-2249.2005.02917.x PMID: 16232223

13. Ramadhan A.M., et al., Immunofibrogenic Gene Expression Patterns in Tanzanian Children with Ocular Chlamydia trachomatis Infection, Active Trachoma and Scarring: Baseline Results of a 4-Year Longitudinal Study. Frontiers in Cellular and Infection Microbiology, 2017. 7: p. 406. https://doi.org/10.3389/fcimb.2017.00406 PMID: 28966918

14. Burton M.J., et al., Pathogenesis of progressive scarring trachoma in Ethiopia and Tanzania and its implications for disease control: two cohort studies. PLoS Negl Trop Dis, 2015. 9(5): p. e0003763. https://doi.org/10.1371/journal.pntd.0003763 PMID: 25970613

15. Hu V.H., et al., Innate immune responses and modified extracellular matrix regulation characterize bacterial infection and cellular/connective tissue changes in scarring trachoma. Infect Immun., 2012. 80(1): p. 121–30. https://doi.org/10.1128/IAI.05965-11 PMID: 22038912

16. Burton M.J., et al., Post-operative recurrent trachomatous trichiasis is associated with increased conjunctival expression of S100A7 (psoriasin). PLoS Negl Trop Dis, 2012. 6(12): p. e1985. https://doi.org/10.1371/journal.pntd.0001985 Epub 2012 Dec 20. PMID: 23285311

17. Burton M.J., et al., Cytokine and fibrogenic gene expression in the conjunctivae of subjects from a Gambian community where trachoma is endemic. Infect Immun., 2004. 72(12): p. 7352–7356. https://doi.org/10.1128/IAI.72.12.7352-7356.2004 PMID: 15557667

18. Burton M.J., et al., Active trachoma is associated with increased conjunctival expression of IL17A and profibrotic cytokines. Infect Immun., 2011. 79(12): p. 4977–83. https://doi.org/10.1128/IAI.05718-11 Epub 2011 Sep 12. PMID: 21911461
23. Faal N., et al., Conjunctival FOXP3 expression in trachoma: do regulatory T cells have a role in human ocular Chlamydia trachomatis infection? PLoS.Med., 2006. 3(8): p. e266. https://doi.org/10.1371/journal.pmed.0030266 PMID: 16881731
24. Bobo L., et al., Evidence for a predominant proinflammatory conjunctival cytokine response in individuals with trachoma. Infect.Immun., 1996. 64(8): p. 3273–3279. PMID: 8757864
25. Stellari F.F., et al., Azithromycin inhibits nuclear factor-kappaB activation during lung inflammation: an in vivo imaging study. Pharmacol Res Perspect, 2014. 2(5): p. e00058. https://doi.org/10.1002/prp2.58 PMID: 25505605
26. Ratzinger F., et al., Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. Sci Rep, 2014. 4: p. 7438. https://doi.org/10.1038/srep07438 PMID: 25500904
27. Murphy B.S., et al., Azithromycin alters macrophage phenotype. J Antimicrob Chemother, 2008. 61(3): p. 554–60. https://doi.org/10.1093/jac/dkn007 PMID: 18230686
28. Poachanukoon O., et al., Macrolides attenuate phorbol ester-induced tumor necrosis factor-alpha and mucin production from human airway epithelial cells. Pharmacology, 2014. 93(1–2): p. 92–9. https://doi.org/10.1159/000358366 PMID: 24556631
29. Giamarellos-Bourboulis E.J., Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents, 2008. 31(1): p. 12–20. https://doi.org/10.1016/j.ijantimicag.2007.08.001 PMID: 17935949
30. Dawson C.R., Jones B.R., and Tarizzo M.L., Guide to Trachoma Control. 1981, Geneva: World Health Organization.
31. Thylefors B., et al., A simple system for the assessment of trachoma and its complications. Bull.World Health Organ., 1987. 65(4): p. 477–483. PMID: 3500800
32. Roberts C.H., et al., Development and evaluation of a next-generation digital PCR diagnostic assay for ocular Chlamydia trachomatis infections. J Clin Microbiol, 2013. 51(7): p. 2195–203. https://doi.org/10.1128/JCM.00622-13 PMID: 23637300
33. Butcher R., et al., Reduced-cost Chlamydia trachomatis-specific multiplex real-time PCR diagnostic assay evaluated for ocular swabs and use by trachoma research programmes. J Microbiol Methods, 2017.
34. Livak K.J. and Schmittgen T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 25(4): p. 402–8. https://doi.org/10.1006/meth.2001.1262 PMID: 11846609
35. Benjamini Y. and Hochberg Y., Controlling the False Discovery Rate:a Practical and Powerful Approach to Multiple Testing. J R.Statistics Soc., 1995. 57: p. 289–300.
36. West S.K., et al., Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control. Ophthalmoic Epidemiol., 2015. 22(3): p. 170–5. https://doi.org/10.1039/c30651936 PMID: 26155874
37. bu El-Asrar A.M., et al., Expression of growth factors in the conjunctiva from patients with active trachoma. Eye., 2006. 20(3): p. 362–369. https://doi.org/10.1038/sj.eye.6701884 PMID: 15818386
38. Skwor T.A., et al., Role of secreted conjunctival mucosal cytokine and chemokine proteins in different stages of trachomatous disease. PLoS.Negl. Trop.Dis., 2008. 2(7): p. e264. https://doi.org/10.1371/journal.pntd.0000264 PMID: 18629887
39. Amsden G.W., Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother, 2005. 55(1): p. 10–21. https://doi.org/10.1093/jac/dkh519 PMID: 15590715
40. Escalante M.G., et al., Comparison of Azithromycin and Amoxicillin Prior to Dental Implant Placement: An Exploratory Study of Bioavailability and Resolution of Postoperative Inflammation. Journal of periodontology, 2015. 86(11): p. 1190–1200. https://doi.org/10.1902/jop.2015.150024 PMID: 26292749
41. Lorenzo M.-J., et al., Lung inflammatory pattern and antibiotic treatment in pneumonia. Respiratory Research, 2015. 16(1): p. 15.
42. Gieilen V., Johnston S.L., and Edwards M.R., Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J, 2010. 36(3): p. 646–54. https://doi.org/10.1183/09031936.00095809 PMID: 20150207
43. Murphy D.M., et al., Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells. J Heart Lung Transplant, 2008. 27(11): p. 1210–6. https://doi.org/10.1016/j.healun.2008.07.026 PMID: 18971093
44. Verleden S.E., et al., Azithromycin decreases MMP-9 expression in the airways of lung transplant recipients. Transpl Immunol, 2011. 25(2–3): p. 159–62. https://doi.org/10.1016/j.trim.2011.06.006 PMID: 21740970
45. Emmez H., et al., Immunomodulatory effectiveness of azithromycin in prevention of postlaminectomy epidural fibrosis. Neurological Research, 2011. 33(4): p. 344–348. https://doi.org/10.1179/016164111X12767786356471 PMID: 20810030

46. Langtry H.D. and Balfour J.A., Azithromycin. A review of its use in paediatric infectious diseases. Drugs, 1998. 56(2): p. 273–97. https://doi.org/10.2165/00003495-199856020-00014 PMID: 9711451

47. Leach A.J., et al., A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis, 1997. 24(3): p. 356–62. https://doi.org/10.1093/clinids/24.3.356 PMID: 9114185

48. Keenan J.D., et al., Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis, 2011. 52(7): p. 883–8. https://doi.org/10.1093/cid/cir069 PMID: 21427395

49. Keenan J.D., et al., Mass azithromycin distribution for reducing childhood mortality in sub-Saharan Africa. The New England Journal of Medicine, 2018: p. https://doi.org/10.1056/NEJMoa1715474